ANNUAL REPORT 2026 49 13. Subsidiaries 2026 ownership interest 2025 ownership interest Nyrada Pty Ltd 100% 100% Norbio No.2 Pty Ltd 100% 100% Cardio Therapeutics Pty Ltd 100% 100% 14. Events after reporting period On 6 July 2026, the Consolidated Entity announced that it had commenced patient dosing in its Phase IIa PROTECT-MI clinical trial and continued progress with clinical trial site activations and recruitment activities. No other matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the Consolidated Entity's operations, the results of those operations, or the Consolidated Entity's state of affairs in future financial years. 15. Cash flow information Reconciliation of loss after income tax to net cash used in operating activities 2026 2025 $ $ Loss after income tax expense for the year (6,557,243) (4,845,671) - - Adjustments for: Depreciation & amortisation 3,211 3,777 Share-based payments 2,524,033 177,218 Change in operating assets and liabilities Decrease/(increase) in trade and other receivables 340,087 (1,235,520) Increase/(decrease) in trade and other payables (868,867) 802,095 Increase/(decrease) in employee benefits 45,552 46,154 (4,513,227) (5,051,947) Reconciliation of Cash Cash and cash equivalents at the end of financial year as included in the statement of cash flows is reconciled to the related items in the statement of financial position as follows: 2026 2025 $ $ Cheque account 274,280 40,501 USD account 547,109 118,993 Saving bonus 3,063,192 2,771,107 Term deposit 4,500,000 - 8,384,581 2,930,601
RkJQdWJsaXNoZXIy MjE2NDg3